Corporate Governance Policy (Revised)
Corporate Governance Policy (Revised) Read more
Roche acquires mySugr to form a leading open platform for digital diabetes management
Basel, 30 June 2017 Roche acquires mySugr to form a leading open platform for digital diabetes management mySugr will become an integral part of Roche’s new patient-centred digital health services in diabetes care Healthcare providers can continue to utilise existing Accu-Chek tools to make better and faster therapy decisions while improving communication with their patients... Read more
Roche’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma
Basel, 30 June 2017 Roche’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options First PRIME designation for a... Read more
New FDA-Cleared Microbroth Dilution Susceptibility Testing Plate Expands Patient Treatment Options for Gram Negative Infections
New antimicrobial options, including ceftolozane/tazobactam and ceftazidime/avibactam, and extended dilution ranges enable targeted treatment recommendations (PRNewsfoto/Thermo Fisher Scientific Inc.) EAST GRINSTEAD, England, June 29, 2017 /PRNewswire/ — A new FDA-cleared microbroth dilution plate for antimicrobial susceptibility (AST) of Gram negative organisms is now available in the U.S., including two of the latest novel compounds, ceftolozane/tazobactam and ceftazidime/avibactam. The... Read more
Thermo Fisher Scientific Adds Three New Products to Leading Semiconductor Portfolio
New products designed to help semiconductor failure analysis labs achieve higher volumes of samples and faster time-to-data HILLSBORO, Ore., June 29, 2017 /PRNewswire/ — For semiconductor manufacturers seeking fast, high-quality electrical and physical failure analysis, Thermo Fisher Scientific today announced three new additions to its broad portfolio of semiconductor failure analysis workflows. The company will demonstrate these products and... Read more
Swift Biosciences Launches Next Phase of Company Growth and Expansion
Company completes Series D funding and adds two new directors to board (ANN ARBOR, Mich. – June 29, 2017) Swift Biosciences, a leading provider of innovative library prep solutions for genomic sequencing, today announced the completion of a Series D funding raise of $12.2 million. The company also announced the addition of two new directors to... Read more
ENZO BIOCHEM REPORTS DELAWARE COURT RULING
NEW YORK, NY, June 29, 2017 – Enzo Biochem Inc. (NYSE: ENZ) reported today that a federal judge for the U.S. District Court for the District of Delaware has entered an order in the actions entitled Enzo Life Sciences, Inc. v. Gen-Probe Incorporated, Enzo Life Sciences, Inc. v. Hologic, Inc., Enzo Life Sciences, Inc. v. Roche Molecular... Read more
The New SCIEX Clinical AB SCIEX TRIPLE QUAD™ 4500MD LC-MS/MS System Obtains CFDA Approval as Medical Device for in vitro Diagnostic Use
The AB SCIEX TRIPLE QUAD™ 4500MD LC-MS/MS system has been approved by the China Food and Drug Administration (CFDA) and meets the market access requirements for medical device products. 1 June 29, 2017 Shanghai, China — SCIEX Diagnostics, the in vitro diagnostics division of SCIEX, a global leader in mass spectrometry in the life sciences industry, announced today that... Read more
Gyros Protein Technologies introduces new ADA solution for immunogenicity market
Developed to support assay development and validation for detection of anti-drug antibodies Uppsala, Sweden, June 29th, 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced it has launched a new version of its anti-drug antibody (ADA) solution for the immunogenicity market. ... Read more
Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) today announced its Extended RAS Panel, an FDA-approved next-generation sequencing (NGS) kit that meets the newly published guidelines for evaluation of colorectal cancer from the American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), the Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology... Read more